MORF4L2 and neoplasm: However, the use of matched miRNA and transcript data, such as miR-3156-5p and MORF4L2 respectively, may be a way of refining and improving currently available biomarker tests for monitoring NET disease and progression in MEN1 patients, as it would be expected that miR-3156-5p levels would decrease while MORF4L2 levels simultaneously increase with increasing tumour burden.